OPR - Delayed Quote • USD VTRS Jul 2024 18.000 call (VTRS240719C00018000) Follow 0.0500 0.0000 (0.00%) As of February 20 at 1:34 PM EST. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for VTRS240719C00018000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: VTRS 11 Best Low Price Pharma Stocks To Invest In Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris 3 Generic Drug Stocks to Watch Amid Challenging Market Prospects Bill Miller’s Latest 13 Stock Picks Viatris to Report First Quarter 2024 Financial Results on May 9, 2024 Viatris Appoints Corinne Le Goff as Chief Commercial Officer Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada Competition watchdog says HRT drug deal could raise prices UPDATE 1-UK watchdog says Theramex-Viatris deal raises competition concerns UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent Teva, Viatris win new chance to challenge J&J schizophrenia drug patent Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
